

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 1, 2004

IFW

Elaine Willig

Attorney Docket No. CHM-015

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Prasad DEVARAJAN et al.

Serial No.: 10/811,130

Filed: March 26, 2004

METHOD AND KIT FOR DETECTING THE EARLY ONSET OF  
RENAL TUBULAR CELL INJURY

:  
: Confirmation No. 2792  
: Group Art Unit 1653  
:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO  
37 CFR 1.56, 1.97 and 1.98**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.56, 1.97 and 1.98, Applicant request the Examiner to make of record the documents listed on the attached PTO/SB/08 form. Copies of the listed documents that are not U.S. patent documents are also enclosed. In accordance with MPEP 609, the Examiner is requested to initial each document listed on the attached PTO/SB/08 form in the space provided, make a copy of the initialed form, and return the copy to Applicants' attorney.

The documents listed on the attached PTO/SB/08 form came to Applicant's attorney's attention as a result of an International Search Report (copy enclosed) for the PCT patent application corresponding to the above application.


This submission does not represent that a search has been made or that no closer art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This paper and the enclosed documents are being submitted in accordance with 37 CFR 1.97(b)(3), i.e., prior to a first Office Action on the merits. Moreover, this paper and the enclosed documents are being submitted in accordance with 37 CFR 1.97(c)(1). Applicant states that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this statement. Therefore, no fee is believed to be due.

Respectfully submitted,


For: P. DEVARAJAN et al.

By   
Daniel F. Nesbitt  
Attorney for Applicant  
Registration No. 33,746  
(513) 229-0383  
Customer Number 38155

November / , 2004

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



*Complete if Known*

Application Number	10/811,130
Filing Date	March 26, 2004
First Named Inventor	Prasad DEVARAJAN et al.
Art Unit	1653
Examiner Name	
Attorney Docket Number	CHM-015

1 of 1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
		US-	6,447,989	09/10/2002	Comper	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LI YAN et al. The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL), J. Biol. Chem., 05 October 2001, Vol. 276, No. 40, pages 37258-37265	
		MONIER et al., Gelatinase isoforms in urine from bladder cancer patients. Clinica Chimica Acta. September 2000, Vol. 299, (1-2), pages 11-23	
		ELNEIHOUM et al. Lukocyte Activation Detected by Increased Plasma Levels of Inflammatory Mediators in Patients with Ischemic Cerebrovascular Diseases. Stroke. (1996), Vol 27, pages 1734-1738	

Examiner  
Signature

Date  
Considered